BAM
VKTX icon

Belpointe Asset Management’s Viking Therapeutics VKTX Stock Holding History

Belpointe Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100
Closed -$1.67K – 3296
2023
Q1 		$1.67K Buy
+100
New +$1.03K ﹤0.01% 3359

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Belpointe Asset Management's VKTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 100 shares — an estimated $1.67K sold.

Belpointe Asset Management first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $1.67K in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 100 Viking Therapeutics shares in Q2 2023, an estimated $1.67K.
  • Belpointe Asset Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Viking Therapeutics position peaked at $1.67K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.